A CELEBRATION OF INNOVATION

November 11, 2015

presented with support from

LSU Health Sciences Center
Office of Academic Affairs

The Foundation for the
LSU Health Sciences Center
PROGRAM

11:00 AM  Networking

11:15 AM  Welcome and Introduction
          Larry H. Hollier, MD
          Chancellor

11:20 AM  Keynote Address
          P.K. Scheerle, RN
          CEO & Founder, Gifted Healthcare

11:30 AM  Awards Presentation
          Patrick E. Reed, MS, RTTP
          Director, Office of Technology Management

Noon     Closing Remarks
          Joseph M. Moerschbaecher, III, PhD
          Vice Chancellor for Academic Affairs

12:15 PM  Luncheon
          Chancellor’s Dining Room, 3rd Floor
Innovation Award Winners & Achievements

Haydee E. P. Bazan, PhD
  Dr. Haydee Bazan helped develop a novel therapeutic compound that reduces swelling, and enhances survival, proliferation and wound healing of damaged corneal cells. This compound can also be used to form an improved storage solution for corneal tissue prior to transplantation.

Nicolas G. Bazan, MD, PhD
- Exclusive License Agreement for analgesic therapeutic compounds, effective 12/11/13

Chu Chen, PhD
- Exclusive License Agreement for a therapeutic compound cocktail for neurodegenerative diseases, effective 1/15/15

William C. Claycomb, PhD
- Nonexclusive License Agreement for novel research materials, effective 4/17/14

Kevin N. Dietz, PhD
- US Patent 8,304,521, “Phospho-specific Anti-Pax3 Antibodies” issued 11/6/12
  Dr. Dietz helped develop a panel of highly-specific antibodies to key regulatory modifications on the protein Pax3 and its cancer-causing counterpart Pax3-FOXO1. Such antibodies present a useful tool for a broad array of applications, including potential as both basic research and clinical uses.
- Nonexclusive License Agreement for novel research materials, effective 6/30/13
- Nonexclusive License Agreement for novel research materials, effective 12/11/14

Jeffrey D. Erickson, PhD
- Nonexclusive License Agreement for novel research materials, effective 3/1/15

Paul Fidel, Jr., PhD
  Dr. Fidel helped invent a simple, removable intraoral device broadly applicable to research involving prostodontics materials, biofilms, or prosthetic-associated infections.

Angela Foley, MS, MT (ASCP)
- Exclusive License Agreement for copyright-protected case-based educational materials for hematology, effective 5/1/14
Timothy P. Foster, PhD

- USA Patent 9,011,845, “Methods for Treatment of Inflammatory and Infectious Viral Diseases,” issued 4/21/15
  Dr. Foster helped develop a therapeutic method to treat drug-resistant viral infections by inhibiting associated pathogenic inflammation and neovascularization while simultaneously promoting tissue healing.

  Dr. Foster helped develop a therapeutic method to inhibit pathogenic inflammation and neovascularization of corneal tissue in an eye infected with a drug-resistant virus, while simultaneously promoting healing of damaged cornea.

Harry J. Gould, III, MD, PhD

- USA Patent 8,921,320, “Targeted Osmotic Lysis of Cancer Cells,” issued 12/30/14
  Dr. Gould helped develop a new therapeutic method to destroy cancer cells called Targeted Osmotic Lysis.

- Limited Right of Exclusive Negotiation Agreement for a therapeutic method for cancer treatment, effective 4/8/13

Daniel S. Haun, MHS

- Exclusive License Agreement for copyright-protected case-based educational materials for hematology, effective 5/1/14

Jiucheng He, MD, PhD

  Dr. He helped develop a novel therapeutic compound that reduces swelling, enhances survival, proliferation and wound healing of damaged corneal cells. This compound can also be used to form an improved storage solution for corneal tissue prior to transplantation.

James M. Hill, PhD

- USA Patent 9,011,845, “Methods for Treatment of Inflammatory and Infectious Viral Diseases,” issued 4/21/15
  Dr. Hill helped develop a therapeutic method to treat drug-resistant viral infections by inhibiting associated pathogenic inflammation and neovascularization while simultaneously promoting tissue healing.

  Dr. Hill helped develop a therapeutic method to inhibit pathogenic inflammation and neovascularization of corneal tissue in an eye infected with a drug-resistant virus, while simultaneously promoting healing of damaged cornea.
Charles W. Hilton, MD

- **US Patent 8,393,905**, “An Improved Medical Simulation Computer System,” issued 3/12/13
  
  Dr. Hilton helped develop a medical simulation system that provides a more realistic training method for doctors. This new system allows for multiple executing simulated scenarios to exchange information and communicate status.

- LIFT^2^ Grant, “Development and Dissemination of a Software Interface,” awarded 5/5/15
  
  Dr. Hilton is optimizing a medical simulation system that provides a more realistic training method for doctors.

Andrew Hollenbach, PhD

  
  Dr. Hollenbach helped develop a panel of highly-specific antibodies to key regulatory modifications on the protein Pax3 and its cancer-causing counterpart Pax3-FOXO1. Such antibodies present a useful tool for a broad array of applications, including potential as both basic research and clinical uses.

- Nonexclusive License Agreement for novel research materials, effective 6/30/13

- Nonexclusive License Agreement for novel research materials, effective 12/11/14

Daniel R. Kapusta, PhD

- LIFT^2^ Grant, “Kappa-opioid Agonists for Therapeutic Uses,” awarded 7/15/14
  
  Dr. Kapusta is testing compounds to protect, prevent and treat kidney injury.

Aaron D. Martin, MD, MPH

- LIFT^2^ Grant, “Apparatus and Method for Tissue Approximation and Fixation in Tubular Biologic Structures,” awarded 7/15/14
  
  Dr. Martin is developing a prototype and testing of a biodegradable urethral scaffold to treat children with urinary conditions.

Charles Nichols, PhD

- Exclusive License Agreement for an anti-inflammatory therapeutic compound, effective 6/8/15

Augusto Ochoa, MD

  
  Dr. Ochoa helped develop a therapeutic method to treat drug-resistant viral infections by inhibiting associated pathogenic inflammation and neovascularization while simultaneously promoting tissue healing.

  
  Dr. Ochoa helped develop a therapeutic method to inhibit pathogenic inflammation and neovascularization of corneal tissue in an eye infected with a drug-resistant virus, while simultaneously promoting healing of damaged cornea.
John T. Paige, MD
- LIFT² Grant, “Development and Dissemination of a Software Interface,” awarded 5/5/15
  - Dr. Paige is optimizing a medical simulation system that provides a more realistic training method for doctors.

Dennis Paul, PhD
  - Dr. Paul helped develop a new therapeutic method to destroy cancer cells called Targeted Osmotic Lysis.
- Limited Right of Exclusive Negotiation Agreement for a therapeutic method for cancer treatment, effective 4/8/13
- Exclusive License Agreement for analgesic therapeutic compounds, effective 12/11/13

Francesca Peruzzi, PhD
- LIFT² Grant, “miR-3189-3p as a Tumor Suppressor,” awarded 5/5/15
  - Dr. Peruzzi is developing a small construct for the treatment of glioblastoma, the most common and most aggressive malignant brain tumor.

Seth Pincus, MD
- LIFT² Grant, “Improved Double Variable Domain Antibodies to HIV,” awarded 5/5/15
  - Dr. Pincus is developing broadly neutralizing anti-HIV antibodies for the prevention and treatment of HIV infection.

Alison J. Quayle, PhD
- Nonexclusive License Agreement for novel research materials, effective 12/11/14
- Nonexclusive License Agreement for novel research materials, effective 1/1/15

Eugene A. Woltering, MD, FACS
- US Patent 8,334,000, “Antiangiogenic Agents from Plant Extracts, Gallic Acid, and Derivatives,” issued 12/18/12
  - Dr. Woltering helped develop a method to inhibit angiogenesis, or the growth of new blood vessels, using a natural extract from the Rubus plant. This method may be used to treat diseases whose pathogenesis includes an increase in angiogenesis, such as psoriasis.
  - Dr. Woltering helped develop a method to inhibit angiogenesis, or the growth of new blood vessels, using an extract from the Noni plant. This method may be used to treat diseases whose pathogenesis includes an increase in angiogenesis, such as psoriasis.
- Limited Right of Exclusive Negotiation Agreement for a diagnostic imaging agent, effective 3/16/15
Hong Xin, MD, PhD
LIFT² Grant, “Peptide Vaccines and Related Antibodies Protect against Fungal Infections,” awarded 5/5/15
Dr. Xin is developing peptide vaccines and related antibodies for the active and passive immunization against candidiasis.

Xiaoming Xu, PhD
Dr. Xu developed novel fluoride-releasing compositions that can be include in different dental materials, such as restorative fillings, to reduce the number of cavities in a patient, particular those occurring on the margins of the restorative materials.

LIFT² Grant, “Antimicrobial Thermoplastic Polyurethanes,” awarded 7/15/14
Dr. Xu is developing antimicrobial materials to reduce the chance of hospital infections from invasive medical devices.

Alika Yu, DDS
Dr. Yu helped invent a simple, removable intraoral device broadly applicable to research involving prosthodontics materials, biofilms, or prosthetic-associated infections.

Jian Zhang, PhD
Exclusive License Agreement for a therapeutic compound cocktail for neurodegenerative diseases, effective 1/15/15